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Received 26 November 2005; received in revised form 20 July 2007; accepted 14 August 2007AbstractObjective: To describe the three-step hysteroscopic endometrial ablation (EA) technique without endometrial preparation, and its long-term
outcomes.
Study design: Four hundred and thirty-eight premenopausal women with menorrhagia or menometrorrhagia underwent three-step hystero-
scopic EA, which consists of rollerball ablation of the fundus and cornual regions, a cutting loop endomyometrial resection of the rest of the
cavity, and rollerball redessication of the whole pre-ablated uterine cavity. The main outcome measures were menstrual status, level of
satisfaction with the procedure, and the need for repeat ablation or hysterectomy. Questionnaires were completed for 385 women (87.9%) with
a mean follow-up of 48.2 months.
Results: One hundred and eighty-four responders (47.8%) reported amenorrhea; 177 (46%) had light to normal flow. One patient (0.3%)
underwent repeat ablation and 20 (5.2%) underwent hysterectomy: 15 (3.9%) because of endometrial ablation failure and 5 (1.3%) because of
indications unrelated to the ablation (three cases of atypical endometrial hyperplasia and two cases of fibroids). Two hundred and ninety-two
patients (75.8%) were very satisfied, and 78 (20.3%) satisfied with the results. No major complications occurred and three women (0.8%)
became pregnant during the follow-up period.
Conclusions: EA is safe and effective means of treating of menorrhagia and menometrorrhagia in premenopausal women, and helps avoid
hysterectomy in 95% of patients suffering from heavy bleeding, with or without uterine fibroids. Women should be informed that the
procedure is not contraceptive and that pregnancy is possible after treatment.
# 2007 Elsevier Ireland Ltd. All rights reserved.
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Menorrhagia is a significant cause of premenopausal
morbidity, accounting for 12% of referrals to gynecologists
[1]. Endometrial ablation is a well-established means of
treating heavy menstrual bleeding that has a number of
advantages over hysterectomy: the avoidance of major
surgery, a short operative time, a short hospital stay, and a* Corresponding author at: Department of Obstetrics and Gynecology,
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doi:10.1016/j.ejogrb.2007.08.013rapid return to normal activities [2–4]. Most published data
indicate that it is effective in 80–90% of cases, and have a
low complication rate [5–7].
The aim of this study was to describe the surgical details
of the three-step hysteroscopic endometrial ablation (EA)
technique without endometrial preparation, and the long-
term outcomes of the procedure.2. Materials and methods
Between March 1997 and September 2003, 438
consecutive premenopausal women underwent EA for the.
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Table 1
Menstrual pattern after EA
No. Percentage
Amenorrhea 184a 47.8first time at San Camillo Hospital, Trento, Italy: 178 (46.2%)
were treated because of menorrhagia and 260 (53.8%)
because of menometrorrhagia. All of them were evaluated
preoperatively by means of a physical examination, cervical
smear, transvaginal pelvic ultrasonography, diagnostic
office hysteroscopy, and a Novak cannula endometrial
biopsy. The exclusion criteria were significant uterovaginal
prolapse, a uterus larger than at 12 weeks’ gestation, uterine
malignancy or its precursors, a desire for future pregnancy,
and endometriosis or inflammatory pelvic disease. No
pharmacological or surgical pre-thinning of the endome-
trium was used; cefazolin 2 g was administered intrave-
nously before surgery.
The interventions were carried out under spinal or general
anesthesia using a 26F dual-channel irrigating resectoscope
(Karl Storz, Tuttlingen, Germany), a rollerball and a loop
electrode. A 1.5% glycine solution in 3 L bags was used for
uterine distension and irrigation, electronically controlled by
Hamou Endomat (Karl Storz). Fluid balance was very
carefully monitored throughout the procedure in order to
avoid fluid overload. After placing a Graves speculum in the
vagina, the cervix was grasped with Pozzi forceps and
dilated to Hegar No. 10.
The procedure used in all cases was three-step hystero-
scopic EA, which consists of (1) ablation of the fundus and
cornual regions using a 3-mm rollerball set at 130 W, pure
cut; (2) endomyometrial resection of the rest of the cavity
using a 24F cutting loop set at 130 W, pure cut, sparing the
isthmic mucosa; and (3) rollerball redessication of the whole
pre-ablated uterine cavity with 130 W cutting current.
Submucosal fibroids or polyps were resected using the
cutting loop before the second step of the procedure. All of
the patients received a single intravenous bolus of antibiotic.
Endometrial strips, and the removed fibroids and polyps
were sent for histological evaluation.
The patients were followed up by means of telephone
enquiries and retrospective analyses of their medical charts.
The main outcome variables were current menstrual status,
level of satisfaction with the procedure (evaluated using a
five-point ordinal scale ranging from 1 = very dissatisfied to
5 = very satisfied), and the need for repeat ablation or
hysterectomy.
The data were analysed by means of the x2 test and
Fisher’s exact test using Stata 8 statistical software; a p value
of 0.05 was considered statistically significant.
The study was approved by our local Ethics Committee,
and all of the patients gave their informed consent before the
operation.
Hypomenorrhea 150 38.9
Eumenorrhea 27 7
Metrorrhagia 1 0.3
Menorrhagia 2 0.5
Menometrorrhagia 0 0
Spotting 1 0.3
Hysterectomy 20b 5.2
a 63 developed menopausal symptoms during follow-up.
b 11 complained of menometrorrhagia, and one experienced spotting.3. Results
Long-term outcome questionnaires were completed for
385 women (87.9%) with a mean (S.D.) follow-up of
48.2  24.2 months (range 9–86). Their mean age at
treatment was 46.4  4.7 years (range 33–56), medianparity 2 (range 0–6), and mean BMI 23.6  4 (range 16–40).
The median duration of symptoms was 12 months (range 1–
134). One hundred and nineteen patients (30.9%) had
previously undergone conservative surgery, such as dilata-
tion and curettage or operative hysteroscopy; none had
undergone previous endometrial ablation. Preoperative
ultrasonography revealed that 143 patients (37.1%) had
uterine fibroids; 19 women (4.9%) had undergone previous
tubal ligation.
The procedure was performed under spinal anesthesia in
322 patients (83.6%) and under general anesthesia in 63
(16.4%), and was successful in all cases. The mean operating
time was 33.9  12 min (range 8–90) and the mean fluid
deficit was 96.1  241.2 ml (range 0–1500). Uterine fibroids
were resected in 49 cases (12.7%) and polyps in 119
(30.9%). Three hundred and sixty-seven patients (95.3%)
were discharged home within 24 h of the end of the
procedure.
No major complications occurred. The minor short-term
complications were two cases (0.5%) of cervical laceration
during dilatation recognised intraoperatively; eight cases
(2.1%) of hemorrhage, one of which required the application
of a Foley balloon catheter; and two cases (0.5%) of
excessive fluid absorption (>1500 ml) treated by diuretics
and catheterisation. Five patients (1.3%) reported nausea
and vomiting, 1 (0.3%) urinary retention, 13 (3.4%)
headache, and 2 (0.5%) with pyrexia. The long-term
complications included two cases (0.5%) of hematometra
and five (1.3%) of pelvic pain. Three patients (0.8%)
subsequently became pregnant: one reached term without
complications, one experienced an early miscarriage, and
one underwent voluntary abortion for psychosocial reasons.
Histology revealed a normal endometrium in 363 cases
(94.3%), endometrial hyperplasia without atypia in 18
(4.7%), and atypical endometrial hyperplasia in 3 (0.8%).
Uterine fibroids were histopathologically diagnosed in 40
cases (10.4%) and adenomyosis in 14 (3.6%).
There were no statistically significant differences in
general and surgical characteristics between the responders
and non-responders.
Table 1 shows the menstrual pattern of the women at the
time of post-procedural assessment: 184 (47.8%) reported
amenorrhea and 177 (46%) reported light to normal flow.
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Fig. 1. Indications for hysterectomy (no. of patients).
Table 2
Level of satisfaction after EA
No. Percentage
Very satisfied 292 75.8
Satisfied 78 20.3
Neutral 5 1.3
Dissatisfied 2 0.5
Very dissatisfied 8 2.1Only 21 patients required a further intervention: 1 (0.3%)
underwent repeat endometrial ablation and 20 (5.2%)
underwent hysterectomy. The indications for hysterectomy
are shown in Fig. 1: as five patients had indications unrelated
to EA (three cases of atypical endometrial hyperplasia and
two cases of uterine fibroids), the true rate of hysterectomy
due to EA failure was 3.9%. The percentage failure by age at
the time treatment (<44, 44–49 and >49) was, respectively,
5.8%, 5.5% and 5.2%; the differences were not statistically
significant ( p = 0.96). The failures were recorded within 24
months of the procedure in 13 cases, 24–48 months in 4
cases, and >48 months in 4 cases. The success rates in the
two groups of women with long-term follow-up (24–48 and
>48 months) were lower than that in the patients followed
up for <24 months (x2 = 12.5; p < 0.01).
The majority of the women were very satisfied with the
outcome (Table 2). Three hundred and sixty-six of the
respondents to the questionnaire (95.1%) said they would
undergo the same treatment again, and 370 (96.1%) said
they would recommend EA to their best friend.
The data regarding the time taken to return to normal
activities show that 235 women (61%) were back to normal
the day after the procedure, and 14 (3.6%) took more than
eight days to recover.4. Discussion
Endometrial ablation has become a widely accepted
alternative to hysterectomy for the treatment of menorrhagia
since the first-generation laser [8], rollerball [9] and
resection [10] techniques were introduced into gynecolo-
gical practice in the 1980s. Although a number of studies
have demonstrated that these procedures are effective and
safe [6,7], second-generation techniques have been devel-
oped with the aim of making endometrial ablation easier,
safer, quicker and possibly even more effective. These
include the use of heated balloon systems [11], hot salinecirculation [12], microwaves [13], monopolar/bipolar
electrical devices [14], laser devices [15], and cryosurgery
[16]. The results concerning the efficacy and safety of these
newer methods are encouraging, but longer term data are
required in order to establish their role and benefit in clinical
practice [6,17].
Three-step hysteroscopic EA is a minimally invasive
means of treating menorrhagia and menometrorrhagia that
requires hysteroscopic skills and an experienced surgeon. In
the first step, a rollerball is used to destroy the endometrium
of the fundus and cornual regions as this technique is
considered slightly safer than using a loop in terms of
perforation of the thinnest parts of the myometrium [6].
Step 2 involves endomyometrial resection of the rest of
the cavity by means of a loop and, in our series, provided
histological specimens that revealed atypical endometrial
hyperplasia in three cases although their preoperative
endometrial biopsies were negative. These three women
underwent hysterectomy in order to avoid the risk of
progression to endometrial carcinoma. Stovall et al. have
reported that pathological results at hysterectomy do not
agree with histological findings at Novak cannula endo-
metrial sampling in 4% of cases, a problem that could be
eliminated by using visually directed endometrial biopsies
[18]. It should be pointed out that laser, rollerball and
second-generation endometrial ablation techniques do not
provide adequate endometrial tissue for pathological
assessment, thus leading to inappropriate under-treatment
in the presence of pre-malignant and malignant endometrial
diseases. The isthmic mucosa was spared to permit light
menstrual flow and to prevent the risk of hematometra by
maintaining transcervical drainage.
Step 3 is intended to ‘radicalise’ endometrial ablation by
rollerball redessicating of the whole pre-ablated uterine
cavity in order to destroy any residual pockets of
endometrium left after steps 1 and 2. We believe that step
3 is the key to the efficacy of the procedure because ‘radical’
endometrial ablation provides lasting symptom relief and
substantially reduces the risk of hematometra, post-ablation
sterilisation syndrome, and endometrial cancer.
The hysterectomy rate in our series was very low: only
3.9% of the patients were hysterectomised during the
follow-up period due to EA failure.
It has previously been shown that the success rate of EA
declines with the length of follow-up [19,20], and that there
is an inverse correlation with patients’ age [20,21]. The
former was confirmed by our findings but, like Amso et al.
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we did not look for any correlation between age, success rate
and menopausal status.
The majority of our patients were very satisfied with the
results, and no major complications occurred.
Three pregnancies (0.8%) were reported during the
follow-up period, which is in line with other published
findings (0.2–1.6% of pregnancies following endometrial
ablation) [23,24]. Given the low rate of hematometra and
post-ablation sterilisation syndrome in our patients, one
possible explanation is that the pregnancies were related to
regenerated endometrium from the spared isthmus rather
than to incomplete endometrial destruction.
Consideration should also be given to preoperative
endometrial preparation, which has been reported to be
associated with shorter operative times, less fluid absorption
and a better menstrual outcome [6,25]. We did not use any
pharmacological or surgical pre-thinning of the endome-
trium (mainly because of the considerable side effects of
hormonal preparations and the reduced hysteroscopic
visualisation caused by curettage), but this did not seem
to compromise the outcome of EA.
In conclusion, our results show that three-step hystero-
scopic EA without endometrial preparation can lead to a
very high success rate and provide evidence that the
technique is effective and safe in the treatment of
menorrhagia and menometrorrhagia in premenopausal
women with or without uterine fibroids. Women should
be informed that the procedure is not contraceptive and that
pregnancy is possible after treatment.Acknowledgement
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